CD4 and glioblastoma: In our preclinical study, testing ALECSAT on autologous GBM-derived cancer stem cells, the in vitro effect correlated significantly with the blood count of CD4+ cells in the patient.14 This suggests that there may be a benefit in collecting cells for ALECSAT preparation at an even earlier stage, when patients generally have higher blood counts, as also seen in our trial.